Cellebrite DI (NASDAQ:CLBT - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03), Zacks reports. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. Cellebrite DI updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.
Cellebrite DI Stock Down 5.5 %
Shares of Cellebrite DI stock traded down $1.20 during trading hours on Monday, reaching $20.50. 2,971,877 shares of the stock traded hands, compared to its average volume of 1,762,856. Cellebrite DI has a one year low of $9.96 and a one year high of $26.30. The firm has a market capitalization of $4.22 billion, a price-to-earnings ratio of -13.23, a P/E/G ratio of 3.72 and a beta of 1.47. The company has a 50 day moving average price of $22.57 and a 200 day moving average price of $19.23.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the stock. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Friday. Craig Hallum upped their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, Lake Street Capital upped their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $23.43.
Get Our Latest Stock Report on Cellebrite DI
Cellebrite DI Company Profile
(
Get Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
See Also

Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.